STAT+: Pharmalittle: Pfizer projects lower revenue from Covid-19 products; Medicare eyes policy for paying less for accelerated-approval drugs
STAT News
FEBRUARY 1, 2023
… A Medicare official hinted the program might test a policy of paying less for drugs that receive so-called accelerated approvals than for medicines that are granted traditional approvals, STAT tells us. The program is widely considered a success and has worked well for many drugs, but not all work out.
Let's personalize your content